

Cohorts 1 to 3
-35
Screening
-1 3
8
Safety
11
Safety
22
PK
29
PK
57
PK
85
PK
113
Study
discharge
Unit stay
(Dosing day 0)
Cohorts 4 to 8
-35
Screening
-1 3
8
Safety
11
Safety
22
PK
29 30
Unit stay
(Dosing day 29)
36
PK
57 58
64
PK/
Immunisation
85
DTH
87
DTH
92
Study
discharge
Unit stay
(Dosing day 0)
Unit stay
(Dosing day 57)
DTH = delayed type hypersensitivity; PK = pharmacokinetics

FIG. 1

Percentage change in anti-TT IgG and IgM titre versus placebo at Day 85, Cohorts 4 to 8 (95% CI; PP analysis population) adjusted for baseline variability




FIG. 2A




FIG. 2B



Screening period (Patients with moderate to severe AD)
randomisation
Lower dose KY1005 (200 mg)
Higher dose KY1005 (500 mg)
Matching placebo
Lower dose KY1005 (100 mg)
Higher dose KY1005 (250 mg)
Matching placebo
Clinic or telephone visits for efficacy, safety, PK and PD assessments
Clinic or telephone visits for efficacy, safety, PK and PD assessments
End of main study*
Visit 1
Day -29
Day -8
Loading Dose (Visit 2)
Day 1
Visit 18
3 x Maintenance Dose (Visits 6, 10, 14)
Day 29
Day 57
Day 85
Day 113

FIG. 3



Percentage Change in EASI Score from Baseline Over Time: LSM with 95% CI (FAS)
LS means of percentage change from baseline of EASI
0
-20
-40
-60
-80
-100
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Baseline
Day 15
Day 29
Day 57
Day 85
Day 113
Day

FIG. 4



Bar Charts of EASI 50, EASI 75 and EASI 90 Responders Over Time (FAS)
% EASI50 responders
100
90
80
70
60
50
40
30
20
10
0
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Day 15
Day 29
Day 57
Day 85
Day 113

FIG. 5A




FIG. 5B




FIG. 5C

Bar Chart of vIGA 0/1 Responders Over Time (FAS)




FIG. 6A



Proportion of vIGA 0/1 patients, %
100
80
60
40
20
0
Days 113 169 253
Weeks 16 24 36
Amlitelimab low dose 12 10 8
Amlitelimab high dose 10 9 7
Placebo 2 1 1

FIG. 6B



Main study (all patients)
Study extension (responders)
Percentage change in EASI from baseline, mean (SD)
0
-20
-40
-60
-80
-100
Amlitelimab low dose (n=12)
Amlitelimab high dose (n=10)
Placebo (n=2)
Amlitelimab low dose (n=27)
Amlitelimab high dose (n=27)
Placebo (n=24)
Days 1 15 29 57 85 113 169 253
Weeks 1 2 4 8 12 16 24 36

FIG. 6C




~5.5 months without treatment
Last IMP dose
Primary endpoint
KY1005 Low Dose
Subject
Screening
Baseline
Day 15
Day 29
Day 57
Day 85
Day 113
Day 169
Day 253
WD
202-1001
213-1001
304-1002
113-1002
203-1008
204-1004
303-1002
206-1009
206-1002
203-1003
213-1005
212-1001

FIG. 7



Non QC'd output | WD = withdrawn | Cut off: 9 Oct 2020

FIG. 7 (Continued)



Percentage Change from Baseline of SCORAD Over Time by Treatment Regimes: LSM with 95% CI (FAS)
LS means of percentage change from baseline of SCORAD
0
-20
-40
-60
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Baseline
Day 29
Day 57
Day 85
Day 113
Day

FIG. 8



Percentage Change in BSA from Baseline Over Time: LSM with 95% CI (FAS)
LS means of percentage change from baseline of BSA
0
-20
-40
-60
-80
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Baseline
Day 29
Day 57
Day 85
Day 113
Day

FIG. 9



Percentage Change in PO-SCORAD Index from Baseline Over Time:
LSM with 95% CI (FAS)
LS means of percentage change from baseline of POSCORAD
20
0
-20
-40
-60
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Baseline
Day 15
Day 29
Day 57
Day 64
Day 85
Day 113
Day

FIG. 10



Percentage Change in DLQI Total Score from Baseline Over Time:
LSM with 95% CI (FAS)
LS means of percentage change from baseline of DLQI
25
0
-25
-50
-75
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Baseline
Day 15
Day 29
Day 57
Day 64
Day 85
Day 113
Day

FIG. 11



Percentage Change in NRS for Pruritus from Baseline Over Time:
LSM with 95% CI (FAS)
LS means of percentage change from baseline of NRS
0
-20
-40
-60
Treatment
KY1005 low dose
KY1005 high dose
Placebo
Baseline
Day 15
Day 29
Day 57
Day 85
Day 113
Day

FIG. 12



Geometric Mean (95% CI) Serum Concentration of KY1005 Over Time (PK Population) (Main Study)
Geometric mean of KY1005 concentration [ng/mL]
150000
100000
50000
0
1
8
15
29
36
57
64
85
92
113
Day
Treatment
KY1005 low dose
KY1005 high dose

FIG. 13



Geometric Mean (95% CI) Serum Concentration of KY1005 Over Time (PK Population) (Study Extension)
Geometric mean of KY1005 concentration [ng/mL]
150000
100000
50000
0
1 8 15 29 36 57 64 85 92 113 169 253
Day
Treatment
KY1005 low dose
KY1005 high dose

FIG. 14



Overall study design
Group 2
Day -28
125 mg of KY1005, SC
Day 1
OP visits
Final follow-up or End of study visit
Day 92 (± 2 days)
Gap of at least 7 days between dosing of Groups 2 and 3
Group 3
Day -28
250 mg of KY1005, SC
Day 1
OP visits
Final follow-up or End of study visit
Day 92 (± 2 days)
Group 1
Day -28
250 mg of KY1005, IV
Day 1
OP visits
Final follow-up or End of study visit
Day 92 (± 2 days)
Abbreviations: IV = intravenous administration; OP = outpatient visit; SC = subcutaneous administration

FIG. 15

Mean serum concentration-time plots (linear and semi-logarithmic) of KY1005 up to 92 days after single intravenous and subcutaneous doses: PK concentration population (n=8 per group)




FIG. 16A




FIG. 16B

Mean serum concentration-time plots (linear and semi-logarithmic) of KY1005 up to 24 h after single intravenous and subcutaneous doses (n=8 per group)




FIG. 17A




FIG. 17B




FIG. 18A FIG. 18B FIG. 18C FIG. 18D



Dose-normalized KY1005 PK profiles for SC treatment
KY1005 CT-04
Dose-normalized KY1005 Conc. (ug/mL/mg)
0.1
0.01
0.001
0
7
14
21
28
Time (days)
Coloured line and ribbon indicates the geometric mean with 95% confidence interval

FIG. 19

Predicted Cmin at Week 24 for Induction Senarios I-III (varying doses) and IV - XII (varying regimes)




FIG. 20A FIG. 20B




FIG. 20C FIG. 20D




FIG. 20E FIG. 20F

IV MODEL: ../Output/71_Select_Final_Models_IV_SC/02_FINALMODEL_SC_IV_cov
SC assumptions: Fabs1 = 0.779, ka = 0.222, CV(Fabs1) = 0.05, CV(ka) = 0.477

Predicted Cmin at Week 24 for Induction Senarios I-III (varying doses) and IV - XII (varying regimes)




FIG. 21A

FIG. 21B




FIG. 21C

FIG. 21D




FIG. 21E

FIG. 21F

IV MODEL: ../Output/71_Select_Final_Models_IV_SC/02_FINALMODEL_SC_IV_cov
SC assumptions: Fabs1 = 0.779, ka = 0.222, CV(Fabs1) = 0.05, CV(ka) = 0.477




FIG. 22A

FIG. 22B

FIG. 22C

IV MODEL: ../Output/71_Select_Final_Models_IV_SC/02_FINALMODEL_SC_IV_cov
SC assumptions: Fabs1 = 0.779, ka = 0.222, CV(Fabs1) = 0.05, CV(ka) = 0.477




FIG. 23A




FIG. 23B




FIG. 23C




FIG. 23D




FIG. 24A

FIG. 24B

FIG. 24C

FIG. 24D




FIG. 25A

FIG. 25B

FIG. 25C

Effective reference treatment: 0.45 mg/kg Q4W IV
Cmin of effective reference treatment: 3.76 ug/mL



Day -28
Screening Period (Adult patients with moderate to severe AD)
Day 1 - Baseline Randomisation
Day 113 - Primary EP
500mg loading with 250mg Q4W from Day 29
250mg plus Placebo loading with 250mg Q4W from Day 29
125mg plus Placebo loading with 125mg Q4W from Day 29
62.5mg plus Placebo loading with 62.5mg Q4W from Day 29
NA plus Placebo loading with Placebo Q4W from Day 29
Day 169 Response
≥ EASI75 and/or IGA 0/1c
<EASI75b
Day 169 - Re-randomisationa
Withdrawal (Placebo)c
Pre-Week 24 dosec
Loss of clinical response → LTEd
Day 365 - End of study
Enter LTE or Safety Follow-up to Day 449e
Enter LTE

FIG. 26



Correlation between EASI and IL-13 serum levels at baseline*
log 10(IL - 13 [pg/mL])
2.5
2.0
1.5
1.0
0.5
0.0
0
20
40
60
80
EASI
r = 0.4784
p <0.0001
Amlitelimab low dose
Amlitelimab high dose
Placebo

FIG. 27




FIG. 28A

FIG. 28B




FIG. 28C




FIG. 29A

FIG. 29B




FIG. 29C

FIG. 29D




FIG. 29F




FIG. 29E



Ph 2 study: >40% with clear / almost clear skin (16 weeks Q4W)
Proportion of vIGA 0/1 patients, %
60
50
40
30
20
10
0
***
***
44.4
37
8.3
KY1005 low dose (n=27)
KY1005 high dose (n=27)
Placebo (n=24)

FIG. 30




FIG. 31A FIG. 31B




FIG. 32A




FIG. 32B




FIG. 32C




FIG. 33A




FIG. 33B




FIG. 33C




FIG. 34



EASI
Placebo
r=0.6147
p=0.0130
KY1005-high
r=0.2415
p=0.2915
All treatment groups
r=0.3806
p=0.0035
KY1005-low
r=0.3519
p=0.1281
% change in EASI at D113
log10(Fold change of IL-13 at D113)
100
50
0
-50
-100
-150
-1.5
-1.0
-0.5
0.0
0.5
1.0

FIG. 35A



SCORAD
Placebo
r=0.5441
p=0.0316
KY1005-high
r=0.4106
p=0.0721
All treatment groups
r=0.4748
p=0.0002
KY1005-low
r=0.3664
p=0.1120
% change in SCORAD at D113
log10(Fold change of IL-13 at D113)
50
0
-50
-100
-150
-1.5
-1.0
-0.5
0.0
0.5
1.0

FIG. 35B




FIG. 36




FIG. 37C




FIG. 37B




FIG. 37A



Placebo
p=0.3820
p=0.9909
p=0.3710
IL-22:Fold change vs Baseline
10
1
0.1
0.01
Baseline
D29
D113
n=16
KY1005-low
p<0.0001
p=0.2820
p<0.0001
IL-22:Fold change vs Baseline
10
1
0.1
0.01
Baseline
D29
D113
n=20
KY1005-high
p=0.0002
p=0.0933
p=0.0224
IL-22:Fold change vs Baseline
10
1
0.1
0.01
Baseline
D29
D113
n=22

FIG. 38



EASI
Placebo
r=0.5618
p=0.0257
KY1005-high
r=0.3692
p=0.0908
All treatment groups
r=0.4302
p=0.0008
KY1005-low
r=0.4496
p=0.0467
% change in EASI at D113
log10(Fold change of IL-22 at D113)
100
50
0
-50
-100
-150
-2
-1
0
1

FIG. 39A



SCORAD
Placebo
r=0.5500
p=0.0295
KY1005-high
r=0.4454
p=0.0430
All treatment groups
r=0.4703
p=0.0002
KY1005-low
r=0.3279
p=0.1581
% change in SCORAD at D113
log10(Fold change of IL-22 at D113)
50
0
-50
-100
-150
-2
-1
0
1

FIG. 39B



Placebo
IL-22:Fold change vs Baseline
10
1
0.1
0.01
Baseline D29 D113 D169 D253
n=29/24/16/2/1
KY1005-low
IL-22:Fold change vs Baseline
10
1
0.1
0.01
Baseline D29 D113 D169 D253
n=29/26/20/12/9
KY1005-high
IL-22:Fold change vs Baseline
10
1
0.1
0.01
Baseline D29 D113 D169 D253
n=30/27/22/10/6

FIG. 40



(A) IgE
KY1005 low dose
KY1005 high dose
PLACEBO
IgE:Fold change vs Baseline
(B) IL-13
IL-13:Fold change vs Baseline
BL
4
16
24
36
ns
*
**
***
****

FIG. 41




FIG. 41 (Continued)



On-treatment serum levels changes in time IL-31
PLACBO
KY1005 low dose
KY1005 high dose
ns
ns
***
ns
**
ns
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5
Log10(IL-31:Fold change vs Baseline) (median ± 95% CI)
Baseline D29 D113
Baseline D29 D113
Baseline D29 D113

FIG. 42